New treatment for Helicobacter Pylori infection using tegoprazan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of a 10-day sequential treatment for Helicobacter pylori infection that includes tegoprazan, a potassium-competitive acid blocker, compared to a conventional treatment that uses esomeprazole. The study is designed as a randomized controlled trial to assess the eradication rates of H. pylori in patients with confirmed infections. Given the high prevalence of antimicrobial resistance in regions like Korea, this trial aims to explore alternative antibiotic combinations to improve treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients who had H. pylori infection proved by positive test result of urea breath test (UBT), rapid urase test or pathologic examination (warthin-giemsa staining)

Exclusion Criteria:

* congestive heart failure, NYHA III or IV
* end-stage renal disease
* alcoholics
* drug abusers
* pregnant or nursing women

Where it's running

• Seoul National University Bundang Hospital
  Seongnam-si, Gyeonggi-do, South Korea Recruiting

Study contacts

• Principal investigator: Nayoung Kim, Prof. — Seoul National University Bundang Hospital
• Study coordinator: Jungwon Lee, Dr.
• Email: saludos@naver.com
• Phone: 821093567758

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fecal transplant to help eradicate stubborn Helicobacter pylori infection

  This study tests whether giving a fecal microbiota transplant can help people with Helicobacter pylori infection that has not responded to standard treatments.

  Recruiting Phase 4 Sichuan Provincial People's Hospital · Chengdu, Sichuan · NCT07704255

• Fecal-guided simplified vonoprazan plus clarithromycin first-line therapy for H. pylori

  We are testing whether a two-drug regimen of vonoprazan plus clarithromycin clears H. pylori in adults whose fecal PCR shows no clarithromycin resistance mutations.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07439445

• Bismuth-amoxicillin-vonoprazan triple therapy versus bismuth-based quadruple therapy for H. pylori infection

  This will test whether a 14-day bismuth-amoxicillin-vonoprazan triple therapy works better and is as safe as a 14-day bismuth-based quadruple therapy for adults with H. pylori infection.

  Recruiting Kaohsiung Medical University · Kaohsiung City · NCT07358130

• P-CABs plus bismuth quadruple treatment for Helicobacter pylori infection

  This study tests whether using potassium-competitive acid blockers (P-CABs) in bismuth-containing quadruple therapy works better and is safe for adults with H. pylori infection.

  Recruiting Qilu Hospital of Shandong University · Jinan · NCT07285096

• Bismuth versus no bismuth for treating H. pylori-related stomach and duodenal ulcers in children

  This project will try adding bismuth to standard antibiotic and PPI treatment to see if it helps clear H. pylori and heal ulcers in children.

  Recruiting Can Tho University of Medicine and Pharmacy · Can Tho · NCT07260006

• Tegoprazan 50 mg twice daily plus amoxicillin versus vonoprazan 20 mg twice daily plus amoxicillin for H. pylori eradication

  This trial tests whether a 14-day tegoprazan plus amoxicillin regimen works as well as a vonoprazan plus amoxicillin regimen to cure Helicobacter pylori infection in adults.

  Recruiting Phase 2/3 First People's Hospital of Hangzhou · Hangzhou, Zhejiang · NCT07242456

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.